The Experts below are selected from a list of 927 Experts worldwide ranked by ideXlab platform
Richard G Douglas - One of the best experts on this subject based on the ideXlab platform.
-
the effects of topical agents on Paranasal Sinus Mucosa healing a rabbit study
International Forum of Allergy & Rhinology, 2015Co-Authors: Ravi Jain, Raymond Kim, Sharon Waldvogelthurlow, Peter H Hwang, Jillian Cornish, Richard G DouglasAbstract:Background Numerous topical agents have been used intraoperatively to enhance postoperative Mucosal healing or reduce scar formation. However, the histological effects of many of these treatments have not been well described. This study investigates the impact of topical mometasone furoate, acitretin, lactoferrin, and Silastic sheet (Medtronic) on Sinus Mucosal healing in a rabbit model. Methods Forty-eight New Zealand white rabbits underwent defined, localized stripping of a bilateral region of maxillary Sinus Mucosa. One of 6 treatments was placed in 1 maxillary Sinus, and the treatment carrier was applied contralaterally (0.1% mometasone furoate, 0.25% and 0.5% acitretin, lactoferrin, Silastic, and no treatment; n = 8 each group). Rabbits were euthanized after 2 weeks and histological sections were examined with light microscopy. Results Treatment with acitretin 0.25% and 0.5% improved cilial recovery by 0.9 ± 0.5 (p = 0.003) and 0.5 ± 0.5 (p < 0.05), respectively. Acitretin 0.25% treatment also significantly reduced collagen in healing Mucosa (5.1% ± 4.8%, p = 0.04). Conversely, rabbits treated with mometasone furoate 0.1% were more likely to have reduced cilial and goblet cell recovery. Intergroup comparisons demonstrated a significant improvement in cilial recovery scores with both acitretin doses compared with mometasone furoate (p < 0.05) and less collagen deposition in rabbits treated with placebo gel over Silastic (p < 0.05). Mucosa directly underlying a blood clot had a lower cilia score and impaired epithelial recovery (p < 0.001). Conclusion Intraoperatively applied agents have the potential to significantly affect wound healing. Acitretin improved cilial recovery and reduced collagen deposition.
Peter H Hwang - One of the best experts on this subject based on the ideXlab platform.
-
the effects of topical agents on Paranasal Sinus Mucosa healing a rabbit study
International Forum of Allergy & Rhinology, 2015Co-Authors: Ravi Jain, Raymond Kim, Sharon Waldvogelthurlow, Peter H Hwang, Jillian Cornish, Richard G DouglasAbstract:Background Numerous topical agents have been used intraoperatively to enhance postoperative Mucosal healing or reduce scar formation. However, the histological effects of many of these treatments have not been well described. This study investigates the impact of topical mometasone furoate, acitretin, lactoferrin, and Silastic sheet (Medtronic) on Sinus Mucosal healing in a rabbit model. Methods Forty-eight New Zealand white rabbits underwent defined, localized stripping of a bilateral region of maxillary Sinus Mucosa. One of 6 treatments was placed in 1 maxillary Sinus, and the treatment carrier was applied contralaterally (0.1% mometasone furoate, 0.25% and 0.5% acitretin, lactoferrin, Silastic, and no treatment; n = 8 each group). Rabbits were euthanized after 2 weeks and histological sections were examined with light microscopy. Results Treatment with acitretin 0.25% and 0.5% improved cilial recovery by 0.9 ± 0.5 (p = 0.003) and 0.5 ± 0.5 (p < 0.05), respectively. Acitretin 0.25% treatment also significantly reduced collagen in healing Mucosa (5.1% ± 4.8%, p = 0.04). Conversely, rabbits treated with mometasone furoate 0.1% were more likely to have reduced cilial and goblet cell recovery. Intergroup comparisons demonstrated a significant improvement in cilial recovery scores with both acitretin doses compared with mometasone furoate (p < 0.05) and less collagen deposition in rabbits treated with placebo gel over Silastic (p < 0.05). Mucosa directly underlying a blood clot had a lower cilia score and impaired epithelial recovery (p < 0.001). Conclusion Intraoperatively applied agents have the potential to significantly affect wound healing. Acitretin improved cilial recovery and reduced collagen deposition.
-
Human ethmoid Sinus Mucosa: a promising novel tissue source of mesenchymal progenitor cells
Stem Cell Research & Therapy, 2014Co-Authors: Hee-young Park, Peter H Hwang, Dawn T Bravo, Jayakar V NayakAbstract:Introduction The identification of new progenitor cell sources is important for cell-based tissue engineering strategies, understanding regional tissue regeneration, and modulating local microenvironments and immune response. However, there are no reports that describe the identification and isolation of mesenchymal progenitor cells (MPCs) from Paranasal Sinus Mucosa, and compare the properties of MPCs between tissue sources within the sinonasal cavity. We report here the identification of MPCs in the maxillary Sinus (MS) and ethmoid Sinus (ES). Furthermore, we contrast these MPCs in the same individuals with MPCs from two additional head and neck tissue sources of the inferior turbinate (IT) and tonsil (T). Methods These four MPC sources were exhaustively compared for morphology, colony-forming potential, proliferation capability, immunophenotype, multilineage differentiation potential, and ability to produce soluble factors. Results MS-, ES, IT-, and T-MPCs showed similar morphologies and surface phenotypes, as well as adipogenic, osteogenic, and chondrogenic differentiation capacity by immunohistochemistry and qRT-PCR for defined lineage-specific genes. However, we noted that the colony-forming potential and proliferation capability of ES-MPCs were distinctly higher than other MPCs. All MPCs constitutively, or upon stimulation, secrete large amounts of IL-6, IL-8, IL-10, IFN-γ, and TGF-β. After stimulation with TNF-α and IFN-γ, ES-MPCs notably demonstrated significantly higher secretion of IL-6 and IL-10 than other MPCs. Conclusions ES-MPCs may be a uniquely promising source of MPCs due to their high proliferation ability and superior capacity toward secretion of immunomodulatory cytokines.
Joseph G. Arthur - One of the best experts on this subject based on the ideXlab platform.
-
A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinoSinusitis
Nature Genetics, 2019Co-Authors: Ragnar P. Kristjansson, Stefania Benonisdottir, Olafur B. Davidsson, Asmundur Oddsson, Vinicius Tragante, Jon K. Sigurdsson, Lilja Stefansdottir, Stefan Jonsson, Brynjar O. Jensson, Joseph G. ArthurAbstract:Genome-wide-association analyses of datasets from Iceland and the UK identify risk variants for nasal polyps and chronic rhinoSinusitis. Notably, a loss-of-function missense variant in ALOX15 confers protection against both phenotypes, thus identifying a potential target for therapeutic intervention. Nasal polyps (NP) are lesions on the nasal and Paranasal Sinus Mucosa and are a risk factor for chronic rhinoSinusitis (CRS). We performed genome-wide association studies on NP and CRS in Iceland and the UK (using UK Biobank data) with 4,366 NP cases, 5,608 CRS cases, and >700,000 controls. We found 10 markers associated with NP and 2 with CRS. We also tested 210 markers reported to associate with eosinophil count, yielding 17 additional NP associations. Of the 27 NP signals, 7 associate with CRS and 13 with asthma. Most notably, a missense variant in ALOX15 that causes a p.Thr560Met alteration in arachidonate 15-lipoxygenase (15-LO) confers large genome-wide significant protection against NP ( P = 8.0 × 10^−27, odds ratio = 0.32; 95% confidence interval = 0.26, 0.39) and CRS ( P = 1.1 × 10^−8, odds ratio = 0.64; 95% confidence interval = 0.55, 0.75). p.Thr560Met, carried by around 1 in 20 Europeans, was previously shown to cause near total loss of 15-LO enzymatic activity. Our findings identify 15-LO as a potential target for therapeutic intervention in NP and CRS.
Tomonori Takasaka - One of the best experts on this subject based on the ideXlab platform.
-
il 12 receptor β2 and cd30 expression in Paranasal Sinus Mucosa of patients with chronic Sinusitis
European Respiratory Journal, 1999Co-Authors: Hiroyuki Suzuki, Satoru Goto, Katsuhisa Ikeda, Takeshi Oshima, M Furukawa, Tomonori TakasakaAbstract:The aetiology of chronic Sinusitis is still poorly understood. The expression of T-helper 1 (Th1) and T-helper 2 (Th2) cell markers, interleukin (IL)-12 receptor beta2 subunit (IL-12Rbeta2) messenger ribonucleic acid (mRNA) and CD30, respectively, were investigated in the Paranasal Sinus Mucosa of patients with chronic Sinusitis in an attempt to elucidate the involvement of Th1 and Th2 cells in this disease. Anterior ethmoidal Mucosae were surgically obtained from two groups of patients with chronic Sinusitis: those who had allergic rhinitis (allergic group, n=11) and those without allergy (nonallergic group, n=11). IL-12Rbeta2 mRNA was quantified by means of the reverse transcription polymerase chain reaction, and CD30-positive cells were examined immunohistochemically. Both IL-12Rbeta2 mRNA and CD30 were expressed in the Sinus Mucosa of the allergic and nonallergic groups. The proportion of mononuclear cells which were CD30-positive in the Sinus Mucosa was significantly greater in the allergic than in the nonallergic group. The expression levels of IL-12Rbeta2 mRNA were virtually equivalent in both groups. These results suggest a T-helper 2-dominated Mucosal reaction in the allergic compared to the nonallergic group, and indicate T-helper 1 activity in the Sinus Mucosa of both groups. The ubiquity of T-helper 1 cells suggests that they play a role in maintaining local Mucosal defences against foreign antigens, which continually enter the upper respiratory tract.
Ravi Jain - One of the best experts on this subject based on the ideXlab platform.
-
the effects of topical agents on Paranasal Sinus Mucosa healing a rabbit study
International Forum of Allergy & Rhinology, 2015Co-Authors: Ravi Jain, Raymond Kim, Sharon Waldvogelthurlow, Peter H Hwang, Jillian Cornish, Richard G DouglasAbstract:Background Numerous topical agents have been used intraoperatively to enhance postoperative Mucosal healing or reduce scar formation. However, the histological effects of many of these treatments have not been well described. This study investigates the impact of topical mometasone furoate, acitretin, lactoferrin, and Silastic sheet (Medtronic) on Sinus Mucosal healing in a rabbit model. Methods Forty-eight New Zealand white rabbits underwent defined, localized stripping of a bilateral region of maxillary Sinus Mucosa. One of 6 treatments was placed in 1 maxillary Sinus, and the treatment carrier was applied contralaterally (0.1% mometasone furoate, 0.25% and 0.5% acitretin, lactoferrin, Silastic, and no treatment; n = 8 each group). Rabbits were euthanized after 2 weeks and histological sections were examined with light microscopy. Results Treatment with acitretin 0.25% and 0.5% improved cilial recovery by 0.9 ± 0.5 (p = 0.003) and 0.5 ± 0.5 (p < 0.05), respectively. Acitretin 0.25% treatment also significantly reduced collagen in healing Mucosa (5.1% ± 4.8%, p = 0.04). Conversely, rabbits treated with mometasone furoate 0.1% were more likely to have reduced cilial and goblet cell recovery. Intergroup comparisons demonstrated a significant improvement in cilial recovery scores with both acitretin doses compared with mometasone furoate (p < 0.05) and less collagen deposition in rabbits treated with placebo gel over Silastic (p < 0.05). Mucosa directly underlying a blood clot had a lower cilia score and impaired epithelial recovery (p < 0.001). Conclusion Intraoperatively applied agents have the potential to significantly affect wound healing. Acitretin improved cilial recovery and reduced collagen deposition.